pharmaceutical daily

Novartis’ Cosentyx does well compared to Janssen’s Stelara, for psoriasis patients

The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel, Switzerland October 22, 2013. REUTERS/Arnd Wiegmann/File Photo

The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel, Switzerland October 22, 2013. REUTERS/Arnd Wiegmann/File Photo

Novartis has had Cosentyx compared against Janssen’s IL-23 Stelara, and it showed superior improvements for psoriasis patients, it said in a statement Tuesday, noting that it was processed and transmitted by West Corporation.

According to Novartis’ press release, new Clarity data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16 compared to Stelara.

Results from Clarity study presented in 2018 showed Cosentyx was significantly more effective than Stelara in delivering clear and almost clear skin at 12 and 16 weeks. Clarity study met all primary and secondary endpoints, Novartis said.

In addition, new Pprose study data presented as a late-breaker supporting benefit of Cosentyx to improve patient QoL.

“Results strengthen unique position of Cosentyx reimagining care as a rapid and long-lasting complete treatment of psoriatic disease, with 200,000+ patients,” Novartis said in the statement.

Exit mobile version